BACKGROUND: There are currently limited data on the use of the levonorgestrel-releasing intrauterine system (LNG-IUS) for the management of heavy menstrual bleeding (HMB) in women with inherited bleeding disorders (IBDs) particularly on its long-term (>12 months) efficacy. STUDY DESIGN: This study involves a case series of women with IBDs who received the LNG-IUS as treatment for HMB. Menstrual blood loss before its insertion and at the time of follow-up was assessed by the pictorial blood-loss assessment chart (PBAC) and hemoglobin (Hb) concentrations. A questionnaire was used to evaluate quality of life (QOL) during menstruation before and after insertion of the LNG-IUS. RESULTS: Twenty-six women were included. The median duration of LNG-IUS use at follow-up was 33 months (range, 14-103). The median PBAC score decreased from 255 (range, 134-683) to 35 (range, 0-89) with LNG-IUS use. The median Hb concentrations (11.2 to 13.2 g/dL) and QOL scores (median, 26 to 52) improved significantly with LNG-IUS use (p<.01). CONCLUSION: The LNG-IUS appears to be an effective long-term treatment for HMB in women with IBDs.
BACKGROUND: There are currently limited data on the use of the levonorgestrel-releasing intrauterine system (LNG-IUS) for the management of heavy menstrual bleeding (HMB) in women with inherited bleeding disorders (IBDs) particularly on its long-term (>12 months) efficacy. STUDY DESIGN: This study involves a case series of women with IBDs who received the LNG-IUS as treatment for HMB. Menstrual blood loss before its insertion and at the time of follow-up was assessed by the pictorial blood-loss assessment chart (PBAC) and hemoglobin (Hb) concentrations. A questionnaire was used to evaluate quality of life (QOL) during menstruation before and after insertion of the LNG-IUS. RESULTS: Twenty-six women were included. The median duration of LNG-IUS use at follow-up was 33 months (range, 14-103). The median PBAC score decreased from 255 (range, 134-683) to 35 (range, 0-89) with LNG-IUS use. The median Hb concentrations (11.2 to 13.2 g/dL) and QOL scores (median, 26 to 52) improved significantly with LNG-IUS use (p<.01). CONCLUSION: The LNG-IUS appears to be an effective long-term treatment for HMB in women with IBDs.
Authors: Igor Govorov; Lena Ekelund; Roza Chaireti; Petra Elfvinge; Margareta Holmström; Katarina Bremme; Miriam Mints Journal: Exp Ther Med Date: 2016-03-10 Impact factor: 2.447
Authors: Nathan T Connell; Veronica H Flood; Romina Brignardello-Petersen; Rezan Abdul-Kadir; Alice Arapshian; Susie Couper; Jean M Grow; Peter Kouides; Michael Laffan; Michelle Lavin; Frank W G Leebeek; Sarah H O'Brien; Margareth C Ozelo; Alberto Tosetto; Angela C Weyand; Paula D James; Mohamad A Kalot; Nedaa Husainat; Reem A Mustafa Journal: Blood Adv Date: 2021-01-12
Authors: V R Byams; P A Kouides; R Kulkarni; J R Baker; D L Brown; J C Gill; A M Grant; A H James; B A Konkle; J Maahs; M M Dumas; S McAlister; D Nance; D Nugent; C S Philipp; J M Soucie; E Stang Journal: Haemophilia Date: 2011-07 Impact factor: 4.287
Authors: Misha Khalighi; Allison P Wheeler; Oluyemisi A Adeyemi-Fowode; Peter A Kouides; Ramon A Durazo-Arvizu; Kristina Haley; Candice M Dersch; Angela C Weyand; Maureen K Baldwin; Claudia Borzutzky Journal: J Adolesc Health Date: 2022-04-13 Impact factor: 7.830